Cue Biopharma Inc. Company Profile
NASDAQ: CUEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Cue Biopharma at a glance
Cue Biopharma Inc. (NASDAQ: CUE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Cue Biopharma is led by Dr. Shao-Lee Lin M.D., Ph.D. and employs about 29 people. The company's shares have traded publicly since 2018.
At a market capitalization of $163.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001645460, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cue Biopharma do?
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Cue Biopharma Inc.
- Ticker
- NASDAQ: CUE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shao-Lee Lin M.D., Ph.D.
- Employees
- 29
- Headquarters
- 40 Guest Street, Boston, MA, United States
- Phone
- 617 949 2680
- Website
- cuebiopharma.com
- IPO year
- 2018
- Market cap
- $163.52M
- SEC CIK
- 0001645460
Companies similar to Cue Biopharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NKTXNkarta Inc. | 2.27 | -1.73% | $162.59M | vs CUE |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs CUE |
| MSLESatellos Bioscience Inc. | 7.63 | +1.19% | $161.88M | vs CUE |
| PEPGPepGen Inc. | 2.40 | +3.90% | $166.01M | vs CUE |
| DERMJourney Medical Corporation | 5.95 | -3.41% | $167.94M | vs CUE |
| NBPNovaBridge Biosciences ADR | 1.37 | -2.14% | $158.92M | vs CUE |
| VRXAVeraxa Biotech AG | 1.20 | +11.11% | $169.69M | vs CUE |
| ORGOOrganogenesis Holdings Inc. Class A | 1.32 | -1.49% | $169.85M | vs CUE |